[go: up one dir, main page]

MX2007003387A - Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin. - Google Patents

Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin.

Info

Publication number
MX2007003387A
MX2007003387A MX2007003387A MX2007003387A MX2007003387A MX 2007003387 A MX2007003387 A MX 2007003387A MX 2007003387 A MX2007003387 A MX 2007003387A MX 2007003387 A MX2007003387 A MX 2007003387A MX 2007003387 A MX2007003387 A MX 2007003387A
Authority
MX
Mexico
Prior art keywords
cyclosporin
etval
meala
treatment
infection
Prior art date
Application number
MX2007003387A
Other languages
Spanish (es)
Inventor
Rolland-Yves Mauvernay
Pietro Scalfaro
Jean-Maurice Dumont
Gregoire Vuagniaux
Original Assignee
Debiopharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Sa filed Critical Debiopharm Sa
Publication of MX2007003387A publication Critical patent/MX2007003387A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This invention relates to the use in the treatment of HCV infection, either as single active agents or in combination with another active agent, of a cyclosporin having increased cyclophilin binding activity and essentially lacking immunosuppressive activity.
MX2007003387A 2004-10-01 2005-10-03 Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin. MX2007003387A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2004003205 2004-10-01
PCT/IB2005/002940 WO2006038088A1 (en) 2004-10-01 2005-10-03 Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin

Publications (1)

Publication Number Publication Date
MX2007003387A true MX2007003387A (en) 2007-05-23

Family

ID=34959441

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007003387A MX2007003387A (en) 2004-10-01 2005-10-03 Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin.

Country Status (29)

Country Link
US (3) US7439227B2 (en)
EP (1) EP1793844B1 (en)
JP (1) JP4892486B2 (en)
KR (1) KR101191833B1 (en)
CN (1) CN101056648B (en)
AT (1) ATE490778T1 (en)
AU (1) AU2005290984B2 (en)
BR (1) BRPI0515494A (en)
CA (1) CA2580448C (en)
CY (1) CY1114594T1 (en)
DE (1) DE602005025232D1 (en)
DK (1) DK1793844T3 (en)
EA (1) EA012650B1 (en)
ES (1) ES2357587T3 (en)
GE (1) GEP20104960B (en)
HR (1) HRP20110169T1 (en)
IL (1) IL182362A0 (en)
MA (1) MA28950B1 (en)
MX (1) MX2007003387A (en)
NZ (1) NZ554412A (en)
PL (1) PL1793844T3 (en)
PT (1) PT1793844E (en)
RS (1) RS51614B (en)
SG (1) SG139750A1 (en)
SI (1) SI1793844T1 (en)
TN (1) TNSN07084A1 (en)
UA (1) UA88484C2 (en)
WO (1) WO2006038088A1 (en)
ZA (1) ZA200702610B (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
ATE497775T1 (en) 2004-07-14 2011-02-15 Novartis Pharma Gmbh USE OF A COMBINATION OF CYCLOSPORINE AND PEGYLATED INTERFERONS FOR THE TREATMENT OF HEPATITIS C (HCV)
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
ES2314731T3 (en) 2004-11-22 2009-03-16 Astellas Pharma Inc. CYCLOSPORINE ANALOG.
EP1830870A1 (en) * 2004-12-23 2007-09-12 Novartis AG Compounds for flaviviridae treatment
US7897565B2 (en) 2004-12-23 2011-03-01 Novartis Ag Compositions for HCV treatment
AR054778A1 (en) * 2005-06-17 2007-07-18 Novartis Ag USE OF SANGLIFERINA IN HCV
ATE498630T1 (en) 2005-09-30 2011-03-15 Scynexis Inc ARYLALKYL AND HETEROARYLALKYL DERIVATIVES OF CYCLOSPORIN A IN THE TREATMENT AND PREVENTION OF VIRUS INFECTION
NZ567262A (en) 2005-09-30 2011-12-22 Scynexis Inc Cyclosporin derivatives and their use for the treatment and prevention of hepatitis C infection
KR101273681B1 (en) 2005-10-26 2013-06-25 아스텔라스세이야쿠 가부시키가이샤 New cyclic peptide compounds
BRPI0710878A2 (en) 2006-04-11 2015-03-31 Novartis Ag Organic compounds and their uses
ES2361635T3 (en) 2006-05-19 2011-06-20 Scynexis, Inc. CYCLOSPORINS FOR THE TREATMENT AND PREVENTION OF EYE DISORDERS.
SG175621A1 (en) * 2006-10-12 2011-11-28 Novartis Ag Use of modified cyclosporins
US7576057B2 (en) 2006-11-20 2009-08-18 Scynexis, Inc. Cyclic peptides
EP2150269B1 (en) 2007-05-02 2012-11-21 Astellas Pharma Inc. New cyclic peptide compounds
CA2700536A1 (en) 2007-09-26 2009-04-02 Oregon Health & Science University Cyclic undecapeptides and derivatives as multiple sclerosis therapies
WO2009098533A1 (en) * 2008-02-08 2009-08-13 Debiopharm Sa Non -immunosuppressive cyclosporin for the treatment of muscular dystrophy
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
WO2010002428A2 (en) 2008-06-06 2010-01-07 Scynexis, Inc. Novel macrocyclic peptides
KR20110093858A (en) * 2008-11-06 2011-08-18 데비오 레쉑쉐 빠르마슈띠끄 에스.아 Cycloundecapideppeptide Compounds and Use of the Compounds as Drugs
CA2748389A1 (en) 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
AU2010208071C1 (en) 2009-01-30 2013-06-20 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
WO2011070364A1 (en) 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
WO2011141891A1 (en) 2010-05-12 2011-11-17 Debio Recherche Pharmaceutique S.A. Use of cycloundecadepsipeptide compounds
US9217015B2 (en) 2010-07-16 2015-12-22 S&T Global Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
WO2012021796A2 (en) 2010-08-12 2012-02-16 S&T Global, Inc. Novel cyclosporin derivatives for the treatment and prevention of a viral infection
WO2012045704A1 (en) 2010-10-05 2012-04-12 Novartis Ag New treatments of hepatitis c virus infection
AU2011311880B2 (en) 2010-10-08 2014-07-24 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
CN105381450A (en) * 2010-11-30 2016-03-09 诺华有限公司 New treatments of hepatitis c virus infection
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
JO3337B1 (en) * 2010-12-13 2019-03-13 Debiopharm Sa Pharmaceutical Compositions Comprising Alisporivir
WO2012130996A1 (en) 2011-03-31 2012-10-04 Novartis Ag Alisporivir to treat hepatitis c virus infection
JP2014509630A (en) 2011-04-01 2014-04-21 ノバルティス アーゲー Treatment of hepatitis B virus infection alone or complex infection with hepatitis delta virus and associated liver disease
WO2012140082A1 (en) * 2011-04-13 2012-10-18 Novartis Ag Treatment of hepatitis c virus infection with alisporivir
BR112014007247A2 (en) 2011-09-27 2017-03-28 Novartis Ag alisporivir for the treatment of hepatitis C virus infection
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SE1450019A1 (en) 2011-10-21 2014-01-10 Abbvie Inc Methods for treating HCV comprising at least two direct-acting antiviral agents, ribavirin but not interferon
CA2811250C (en) 2011-10-21 2015-08-11 Abbvie Inc. Methods for treating hcv
KR20150013152A (en) 2012-05-07 2015-02-04 노파르티스 아게 Pharmacokinetic modulation with alisporivir
AR090964A1 (en) * 2012-05-09 2014-12-17 Novartis Ag PROCESS FOR THE PREPARATION OF CYCLE UNDECAPEPTIDES
WO2014085623A1 (en) 2012-11-28 2014-06-05 Enanta Pharmaceuticals, Inc. Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
WO2015008223A1 (en) 2013-07-17 2015-01-22 Novartis Ag Treatment of hepatitis c virus infection with alisporivir and ribavirin
KR20160045136A (en) 2013-08-26 2016-04-26 이난타 파마슈티칼스, 인코포레이티드 Cyclosporin analogues for preventing or treating hepatitis c
WO2015136455A1 (en) 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF
EP3623378B1 (en) 2017-05-12 2025-07-02 Chugai Seiyaku Kabushiki Kaisha Method for producing cyclic organic compound

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757520B1 (en) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa CYCLOSPORIN DERIVATIVE, ITS PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2757522B1 (en) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
CA2335903C (en) * 1998-07-01 2009-11-10 Debiopharm S.A. Novel cyclosporin with improved activity profile
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US20060252675A1 (en) 2006-11-09
KR20070073761A (en) 2007-07-10
USRE43371E1 (en) 2012-05-08
ATE490778T1 (en) 2010-12-15
CN101056648A (en) 2007-10-17
UA88484C2 (en) 2009-10-26
HRP20110169T1 (en) 2011-04-30
TNSN07084A1 (en) 2008-06-02
US20090081164A1 (en) 2009-03-26
BRPI0515494A (en) 2008-07-29
CA2580448C (en) 2012-09-18
GEP20104960B (en) 2010-04-26
EA200700725A1 (en) 2007-10-26
CA2580448A1 (en) 2006-04-13
DK1793844T3 (en) 2011-03-21
SI1793844T1 (en) 2011-05-31
IL182362A0 (en) 2007-07-24
DE602005025232D1 (en) 2011-01-20
ZA200702610B (en) 2008-08-27
SG139750A1 (en) 2008-02-29
ES2357587T3 (en) 2011-04-27
EP1793844B1 (en) 2010-12-08
CN101056648B (en) 2012-08-15
CY1114594T1 (en) 2016-10-05
US7439227B2 (en) 2008-10-21
AU2005290984A1 (en) 2006-04-13
AU2005290984B2 (en) 2010-09-09
HK1104236A1 (en) 2008-01-11
PL1793844T3 (en) 2011-05-31
US7772184B2 (en) 2010-08-10
KR101191833B1 (en) 2012-10-16
JP2008514690A (en) 2008-05-08
EA012650B1 (en) 2009-12-30
MA28950B1 (en) 2007-10-01
RS51614B (en) 2011-08-31
PT1793844E (en) 2011-03-10
JP4892486B2 (en) 2012-03-07
NZ554412A (en) 2011-01-28
WO2006038088A1 (en) 2006-04-13
EP1793844A1 (en) 2007-06-13

Similar Documents

Publication Publication Date Title
TNSN07084A1 (en) Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin
EP3530288A3 (en) Methods for treating conditions associated with masp-2 dependent complement activation
WO2004052401A3 (en) Compositions and methods of delivery of pharmacological agents
WO2005095403A3 (en) Macrocyclic compounds as inhibitors of viral replication
MXPA02002895A (en) Topical treatment of streptococcal infections.
WO2006138418A3 (en) Improvement of cognitive performance with sirtuin activators
HUE036559T2 (en) Compositions for increasing telomerase activity and treating hiv infection
WO2001091728A3 (en) Nanoemulsion formulations
WO2005102392A3 (en) Combinations for treating hiv infection
EP2279732A3 (en) Compounds and compositions for delivering active agents
WO2006041641A3 (en) Therapeutic agents with decreased toxicity
SG149872A1 (en) Antagonists of the bradykinin b1 receptor
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
WO2006096774A3 (en) Composition and methods for delivering carbon monoxide (co) and nitric ozide (no) co to tissue using heme proteins as carriers
WO2007007095A3 (en) Pharmaceutical compositions comprising a tgf-beta superfamily member
TNSN06308A1 (en) Macrocyclic compounds as inhibitors of viral replication
WO2006034001A3 (en) Methods of treating hiv infection
WO2005121138A3 (en) Heterotricyclic compounds for use as hcv inhibitors
WO2007022219A3 (en) Dental composition comprising enzyme
AU5158000A (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
SI1729732T1 (en) Anionic hydrogel matrices with ph dependent modified release as drug carriers
WO1998035694A3 (en) A pharmaceutical composition for treating hepatitis b virus (hbv) infection
WO2001070184A3 (en) A composition containing monoterpenes for topical oral administration
CU20070072A7 (en) USE OF [D-MEALA] 3- [ETVAL] 4-CYCLOSPORINE FOR THE TREATMENT OF INFECTION WITH HEPATITIS C AND PHARMACEUTICAL COMPOSITION INCLUDING [D-MEALA] 3- [ETVAL] 4-CYCLOSPORINE
WO2002002763A3 (en) Recombinant staphylococcus aureus peptide deformylase

Legal Events

Date Code Title Description
FG Grant or registration